Management of Intraocular Infections in HIV

References

• Cunningham ET, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med. 1998;339:236–244. doi:10.1056/NEJM199807233390406.
   PubMed Web of Science ®Google Scholar
• Arora N, Schuenemann VJ, Jäger G, et al. Origin of modern syphilis and emergence of a pandemic treponema pallidum cluster. Nat Microbiol. 2016;2:16245. doi:10.1038/nmicrobiol.2016.245.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Giralt J, Pelegrín L, et al. Ocular syphilis—back again: understanding recent increases in the incidence of ocular syphilitic disease. Ocul Immunol Inflamm. 2009;17(3):207–212. doi:10.1080/09273940902741709.
   PubMed Web of Science ®Google Scholar
• Browning DJ. Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. Ophthalmol. 2000;107(11):2015–2023. doi:10.1016/S0161-6420(00)00457-7.
   PubMed Web of Science ®Google Scholar
• Villanueva AV, Sahouri MJ, Ormerod LD, Puklin JE, Reyes MP. Posterior uveitis in patients with positive serology for syphilis. Clin Infect Dis. 2000;30(3):479–485. doi:10.1086/313689.
   PubMed Web of Science ®Google Scholar
• Tucker JD, Li JZ, Robbins GK, et al. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sex Transm Infect. 2011;87(1):4–8. doi:10.1136/sti.2010.043042.
   PubMed Web of Science ®Google Scholar
• Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 2015;64(34–51). bk_AQCmts9b.
   Google Scholar
• Rolfs RT, Joesoef MR, Hendershot EF, et al. The syphilis and HIV study group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med. 1997;337:307–314. doi:10.1056/NEJM199707313370504.
   PubMed Web of Science ®Google Scholar
• Ghanem KG, Erbelding EJ, Wiener ZS, et al. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect. 2007;83:97–101. 409. doi:10.1136/sti.2006.021402.
   PubMed Web of Science ®Google Scholar
• Sena AC, Wolff M, Martin DH, et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. 2011;53:1092–1099. doi:10.1093/cid/cir671.
   PubMed Web of Science ®Google Scholar
• Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch Dermatol. 2005;141:431–433. doi:10.1001/archderm.141.4.431.
   PubMedGoogle Scholar
• Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis. 2004;38:1001–1006. 425. doi:10.1086/cid.2004.38.issue-7.
   PubMed Web of Science ®Google Scholar
• Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis. 2008;47:893–899. doi:10.1086/591534.
   PubMed Web of Science ®Google Scholar
• Pichi F, Ciardella AP, Cunningham ET Jr, et al. Spectral domain optical coherence tomography findings in patients with acute syphilitic posterior placoid chorioretinopathy. Retina. 2014;34:373–384. doi:10.1097/IAE.0b013e3182993f11.
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Nishijima T, Yashiro S, et al. Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era. Sex Transm Infect. 2016;92(8):605–610. doi:10.1136/sextrans-2016-052568.
   PubMed Web of Science ®Google Scholar
• Li JZ, Tucker JD, Lobo AM, et al. Ocular syphilis among HIV-infected individuals. Clin Infect Dis. 2010;51:468–471. doi:10.1086/654797.
   PubMed Web of Science ®Google Scholar
• Fathilah J, Choo MM. The Jarisch-Herxheimer reaction in ocular syphilis. Med J Malaysia. 2003;58:437–439.
   PubMedGoogle Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis – an update. Surv Opthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015.
   PubMed Web of Science ®Google Scholar
• Ang M, Chee SP. Controversies in ocular tuberculosis. Br J Ophthalmol. 2017;101(1):6–9. doi:10.1136/bjophthalmol-2016-309531.
   PubMed Web of Science ®Google Scholar
• Lee C, Agrawal R, Ocular Tuberculosis PC. A clinical conundrum. Ocul Immunol Inflamm. 2016;24(2):237–242. doi:10.3109/09273948.2014.985387.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol. 2017;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep. 2003;52:1–77.
   Google Scholar
• Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr. 2007;44(2):229–234. doi:10.1097/QAI.0b013e31802e2975.
   PubMed Web of Science ®Google Scholar
• Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Handa S, Aggarwal K, et al. The role of dexamethasone implant in the management of tubercular uveitis. Ocul Immunol Inflamm. 2018;26(6):884–892. doi:10.1080/09273948.2017.1400074.
   PubMed Web of Science ®Google Scholar
• Jain L, Panda KG, Basu S Clinical Outcomes of Adjunctive Sustained-Release Intravitreal
   Google Scholar
• Jain L, Panda KG, Basu S. Dexamethasone implants in tuberculosis-associated multifocal serpigenoid choroiditis. Ocul Immunol Inflamm. 2018;26(6):877–883. doi:10.1080/09273948.2017.1383446.
   PubMed Web of Science ®Google Scholar
• Hasanreisoglu M, Gulpinar Ikiz G, Aktas Z, Ozdek S. Intravitreal dexamethasone implant as an option for anti-inflammatory therapy of tuberculosis uveitis. Int Ophthalmol. 2019;39(2):485–490. doi:10.1007/s10792-018-0831-4.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116:797–801. doi:10.1016/j.ophtha.2008.10.033.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology. 2012;119:878–879. doi:10.1016/j.ophtha.2011.12.015.
   PubMed Web of Science ®Google Scholar
• Julian K, Langner-Wegscheider BJ, Haas A, De Smet MD. Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis. Retina. 2013;33(9):1943–1948. doi:10.1097/IAE.0b013e318285cdbe.
   PubMed Web of Science ®Google Scholar
• Sahin O, Ziaei A. The role of methotrexate in resolving ocular inflammation after specific therapy for presumed latent syphilitic uveitis and presumed tuberculosis-related uveitis. Retina. 2014;34(7):1451–1459. doi:10.1097/IAE.0000000000000080.
   PubMed Web of Science ®Google Scholar
• Bansal R, Beke N, Sharma A. Gupta a intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma. BMJ Case Rep. 2013;6:201.
   Google Scholar
• Invernizzi A, Franzetti F, Viola F, Meroni L, Staurenghi G. Optic nerve head tubercular granuloma successfully treated with anti-VEGF intravitreal injections in addition to systemic therapy. Eur J Ophthalmol. 2015;25:270–272. doi:10.5301/ejo.5000528.
   PubMed Web of Science ®Google Scholar
• Jain S, Bajgai P, Tigari B, et al. Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma. J Ophthalmic Inflamm Infect. 2016;6:42. doi:10.1186/s12348-016-0112-1.
   PubMed Web of Science ®Google Scholar
• Jain S, Agarwal A, Gupta V. Resolution of large choroidal tuberculoma following monotherapy with intravitreal ranibizumab. Ocul Immunol Inflamm. 2019;15:1–4. doi:10.1080/09273948.2019.1582786.
   Google Scholar
• Bansal R, Gupta A, Gupta V, Dogra MR, Sharma A, Bambery P. Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. Ophthalmology. 2012;119(11):2334–2342. doi:10.1016/j.ophtha.2012.05.034.
   PubMed Web of Science ®Google Scholar
• Mehta S, Mansoor H, Khan S, Saranchuk P, Isaakidis P. Ocular inflammatory disease and ocular tuberculosis in a cohort of patients co-infected with HIV and multidrug-resistant tuberculosis in Mumbai, India: a cross-sectional study. BMC Infect Dis. 2013;13:225. doi:10.1186/1471-2334-13-225.
   PubMed Web of Science ®Google Scholar
• WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
   Google Scholar
• Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601–610. doi:10.1016/S0002-9394(14)73706-7.
   PubMed Web of Science ®Google Scholar
• Holland GN, Engstrom R, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653–667. doi:10.1016/0002-9394(88)90697-6.
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis in the immunocompromised host. Int Ophthalmol. 1989;13:399–402. doi:10.1007/BF02306488.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Smith RE, Rao NA. Progressive ocular toxo- plasmosis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:742–747. doi:10.1016/S0002-9394(14)73641-4.
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology. 2004;111(4):716–725. doi:10.1016/j.ophtha.2003.07.004.
   PubMed Web of Science ®Google Scholar
• Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immu- nocompromised patients. Ophthalmology. 1994;101:499–507. doi:10.1016/S0161-6420(13)31267-6.
   PubMed Web of Science ®Google Scholar
• Crosson JN, Laird PW, Grossniklaus HE, Hendrick AM. Toxoplasma chorioretinitis diagnosed by histopathology in a patient with AIDS. Retin Cases Brief Rep. 2015;9(2):162–163. doi:10.1097/ICB.0000000000000126.
   PubMedGoogle Scholar
• Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol. 1992;114(2):130–135. doi:10.1016/S0002-9394(14)73975-3.
   PubMed Web of Science ®Google Scholar
• Commodaro AG, Belfort RN, Rizzo LV, et al. Ocular toxoplasmosis: an update and review of the literature. Mem Inst Oswaldo Cruz. 2009;104(2):345–350. doi:10.1590/S0074-02762009000200030.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Torun N, Liesenfeld O. Ocular toxoplasmosis. Ophthalmologe. 2007;104:603–615. doi:10.1007/s00347-007-1535-8.
   PubMed Web of Science ®Google Scholar
• Antoniazzi E, Guagliano R, Meroni V, Pezzotta S, Bianchi PE. Ocular impairment of toxoplasmosis. Parasitologia. 2008;50:35–36.
   PubMedGoogle Scholar
• Arevalo JF, Belfort R Jr, Muccioli C, Espinoza JV. Ocular toxoplasmosis in the developing world. Int Ophthalmol Clin. 2010;50(2):57–69. 62. doi:10.1097/IIO.0b013e3181d26bf4.
   PubMedGoogle Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965–1976. doi:10.1016/S0140-6736(04)16412-X.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Parasites – Toxoplasmosis (Toxoplasma infection). https://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html#tx. Accessed September 25, 2019.
   Google Scholar
• Ryan C, Madalon M, Wortham DW, Graziano FM. Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature. WMJ. 1998;97:23–27.
   PubMedGoogle Scholar
• Schnyder B, Pichler WJ. Allergy to sulfonamides. J Allergy Clin Immunol. 2013;131(1):256–257. e1-5. doi:10.1016/j.jaci.2012.10.003.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869–878. doi:10.1016/S0161-6420(02)00990-9.
   PubMed Web of Science ®Google Scholar
• Opremcak EM, Scales DK, Sharpe MR. Trimethoprim-sulfame- thoxazole therapy for ocular toxoplasmosis. Ophthalmology. 1992;99:920–925. doi:10.1016/S0161-6420(92)31873-1.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective ran- domized trial of trimethoprim/sulfamethoxazole versus py- rimethamine and sulfadiazine in the treatment of ocular toxoplas- mosis. Ophthalmology. 2005;112:1876–1882. doi:10.1016/j.ophtha.2005.05.025.
   PubMed Web of Science ®Google Scholar
• Lasave AF, Díaz-Llopis M, Muccioli C, Belfort R Jr, Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117(9):1831–1838. doi:10.1016/j.ophtha.2010.01.028.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134–141. doi:10.1016/j.ophtha.2010.04.020.
   PubMed Web of Science ®Google Scholar
• Souza CE, Nascimento H, Lima A, Muccioli C, Belfort R Jr. Intravitreal injection of sulfamethoxazole and trimethoprim associated with dexamethasone as an alternative therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2018;26(7):1041–1044. doi:10.1080/09273948.2017.1307420.
   PubMed Web of Science ®Google Scholar
• Silveira C, Jr BR, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41–46. doi:10.1016/S0002-9394(02)01527-1.
   PubMed Web of Science ®Google Scholar
• Felix JP, Lira RP, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014;157(762–766):e1. doi:10.1016/j.ajo.2013.12.022.
   PubMedGoogle Scholar
• Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63–86.
   PubMedGoogle Scholar
• Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immu- nocompetent patients. Ophthalmology. 1999;106:148–153. doi:10.1016/S0161-6420(99)90021-0.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000;182(2):611–615. doi:10.1086/jid.2000.182.issue-2.
   PubMed Web of Science ®Google Scholar
• Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. 1999;13(13):1647–1651. doi:10.1097/00002030-199909100-00007.
   PubMed Web of Science ®Google Scholar
• Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV cohort study. Lancet. 2000;355(9222):2217–2218. doi:10.1016/S0140-6736(00)02407-7.
   PubMed Web of Science ®Google Scholar
• Miro JM, Lopez JC, Podzamczer D, et al. GESIDA 04/98 study group.Discontinuation of primary and secondary Toxoplasma gondiiprophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiret- roviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006;43(1):79–89. doi:10.1086/504872.
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Rochat C, Herbort CP. Necrotizing herpetic retinopathies: a spectrum of herpes virus-induced diseases determined by the immune state of the host. J Oc Immunol Inflamm. 1997;5:259–265. doi:10.3109/09273949709085066.
   PubMed Web of Science ®Google Scholar
• deSmet MD. Differential diagnosis of retinitis and choroiditis in patients with acquired immunodeficiency syndrome. Am J Med. 1992;92(2A):17S–21S. doi:10.1016/0002-9343(92)90332-6.
   PubMedGoogle Scholar
• Dunn JP. Other retinal and choroidal manifestations of HIV infection. In: Stenson SM, Freidberg DN, eds. AIDS and the eye. New Orleans: Contact Lens Assoc of Am; 1995:87–105.
   Google Scholar
• Kim W, Duker JS. Ocular manifestations of human immunodeficiency virus. Sem Ophthalmol. 1996;11:93–106. doi:10.3109/08820539609067467.
   Google Scholar
• Litwak AB. Non-CMV infectious chorioretinopathies in AIDS. Optom Vis Sci. 1995;72(5):312–319.
   Google Scholar
• Holland GN. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive committee of the american uveitis society. Am J Ophthalmol. 1994;117(5):663–667. doi:10.1016/S0002-9394(14)70075-3.
   PubMed Web of Science ®Google Scholar
• Forster DJ, Dugel PU, Frangieh GT, Liggett PE, Rao NA. Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome. Am J Ophthalmol. 1990;ll0:341–348. doi:10.1016/S0002-9394(14)77012-6.
   Google Scholar
• Gore DM, Gore SK, Visser L. Progressive outer retinal necrosis: outcomes in the intravitreal era. Arch Ophthalmol. 2012;130(6):700–706. doi:10.1001/archophthalmol.2011.2622.
   PubMedGoogle Scholar
• Engstrom RE Jr, Holland GN, Margolis TP, et al. The progressive outer retinal necrosis syndrome: a variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology. 1994;101(9):1488–1502. doi:10.1016/S0161-6420(94)31142-0.
   PubMed Web of Science ®Google Scholar
• Pinnolis MK, Foxworthy D, Kemp B. Treatment of progressive outer retinal necrosis with sorivudine. Am J Ophthalmol. 1995;119:516–517. doi:10.1016/S0002-9394(14)71242-5.
   PubMed Web of Science ®Google Scholar
• Jeske DN. Progressive outer retinal necrosis syndrome. Clin Eye Vis Care. 1994;6:158–168.
   Google Scholar
• Margolis TP, Lowder CY, Holland GN, et al. Varicella-zoster virus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1991;112:119–131. doi:10.1016/S0002-9394(14)76690-5.
   PubMed Web of Science ®Google Scholar
• Greven CM, Ford J, Stanton C, et al. Progressive outer retinal necrosis secondary to Varicella zostev virus in acquired immune deficiency syndrome. Retina. 1995;15:14–20. doi:10.1097/00006982-199515010-00003.
   PubMed Web of Science ®Google Scholar
• Friedman SM, Margo CE, Connelly BL. Varicella-zoster virus retinitis as the initial manifestation of the acquired immunodeficiency syndrome [letter]. Am J Ophthalmol. 1994;117:536–538. doi:10.1016/S0002-9394(14)70020-0.
   PubMed Web of Science ®Google Scholar
• Holland GN. The progressive outer retinal necrosis syndrome. [Review]. Int Ophthalmol. 1994;18:163–165. doi:10.1007/BF00915966.
   PubMed Web of Science ®Google Scholar
• Johnston WH, Holland GN, Engstrom RE Jr., Rimmer S. Recurrence of presumed Varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;116:42–50. doi:10.1016/S0002-9394(14)71742-8.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Weinberg DV, Teich SA, et al. Management of Varicella zostev virus retinitis in AIDS. Br J Ophthalmol. 1997;81:189–194. doi:10.1136/bjo.81.3.189.
   PubMed Web of Science ®Google Scholar
• Austin RB. Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management. Clin Eye Vis Care. 2000;12((3–4):119–129. 4. doi:10.1016/S0953-4431(00)00052-7.
   PubMedGoogle Scholar
• Manischewitz JF, Quitman GV Jr, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990;34:373–375. doi:10.1128/AAC.34.2.373.
   PubMed Web of Science ®Google Scholar
• Freitas VR, Fraser-Smith EB, Matthews TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989;12(4):205–212.
   Google Scholar
• Kim SJ, Equi R, Belair ML, Fine HF, Dunn JP. Long-term preservation of vision in progressive outer retinal necrosis treated with combination antiviral drugs and highly active antiretroviral therapy. Ocul Immunol Inflamm. 2007;15(6):425–427. doi:10.1080/09273940701732255.
   PubMed Web of Science ®Google Scholar
• Scott IU, Luu KM, Davis JL. Intravitreal antivirals in the management of patients with acquired immunodeficiency syndrome with progressive outer retinal necrosis. Arch Ophthalmol. 2002: 120(9): 1219–1222. 7
   PubMedGoogle Scholar
• Sittivarakul W, Aui-aree N. Clinical features, management and outcomes of progressive outer retinal necrosis (PORN) in southern Thailand. J Med Assoc Thai. 2009: 92(3): 360–366. 8
   PubMedGoogle Scholar
• Yin PD, Kurup SK, Fischer SH, et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol. 2007;38(3):254–259. doi:10.1016/j.jcv.2006.12.012.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Ahuja A, Van Natta M, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010;117(11):2152–2161. 27. doi:10.1016/j.ophtha.2010.03.031.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR–4):1–207.
   Google Scholar
• Weinberg DV, Lyon AT. Repair of retinal detachments due to herpes Varicella-zoster virus retinitis in patients with acquired immune deficiency syndrome. Ophthalmol. 1997;104(2):279–282.
   Web of Science ®Google Scholar
• Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5–14. doi:10.1086/313843.
   PubMed Web of Science ®Google Scholar
• Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996;114(7):821–827. doi:10.1001/archopht.1996.01100140035004.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623–683.
   PubMedGoogle Scholar
• Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115(5):575–582. doi:10.1016/S0002-9394(14)71453-9.
   PubMed Web of Science ®Google Scholar
• Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis. 2013;57:1351–1361.
   PubMed Web of Science ®Google Scholar
• Skiest DJ. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). Am J Med Sci. 1999;317(5):318–335. doi:10.1016/S0002-9629(15)40535-X.
   PubMed Web of Science ®Google Scholar
• Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology. 1985;92(4):472–484. doi:10.1016/S0161-6420(85)34008-3.
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The cytomegalovirus retreatment trial. Arch Ophthalmol. 1996;114(1):23–33. doi:10.1001/archopht.1996.01100130021004.
   PubMedGoogle Scholar
• Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326(4):213–220. doi:10.1056/NEJM199201233260401.
   PubMed Web of Science ®Google Scholar
• The Studies of Ocular Complications of AIDS Research Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the ganciclovir cidofovir cytomegalovirus retinitis trial. Am J Ophthalmol. 2001;131(4):457–467. doi:10.1016/S0002-9394(01)00840-6.
   PubMed Web of Science ®Google Scholar
• Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346(15):1119–1126. doi:10.1056/NEJMoa011759.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, España E, Muñoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol. 1994;78(2):120–124. doi:10.1136/bjo.78.2.120.
   PubMed Web of Science ®Google Scholar
• Young S, Morlet N, Besen G, et al. High-dose (2000-μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:1404–1410. doi:10.1016/S0161-6420(98)98020-4.
   PubMed Web of Science ®Google Scholar
• Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS. 2005;19(7):735–738. doi:10.1097/01.aids.0000166100.36638.97.
   PubMed Web of Science ®Google Scholar
• Curi AL, Machado DO, Heringer G, Campos WR, Orefice F. Ocular manifestation of cat-scratch disease in HIV-positive patients. Am J Ophthalmol. 2006;141(2):400–401. doi:10.1016/j.ajo.2005.08.072.
   PubMed Web of Science ®Google Scholar
• Wong MT, Dolan MJ, Lattuada CP, et al. Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis. 1995;21:252–260. doi:10.1093/clinids/21.2.352.
   Web of Science ®Google Scholar
• Warren K, Goldstein E, Hung VS, Koehler JE, Richardson W. Use of retinal biopsy to diagnose Bartonella (formerly Rochalimaea) henselae retinitis in an HIV-infected patient. Arch Ophthalmol. 1998;116:937–940. doi:10.1001/archopht.116.7.937.
   PubMedGoogle Scholar
• Merle De Boever C, Mura F, Brun M, Reynes J. Ocular bartonellosis in an HIV-HVC coinfected patient. Med Mal Infect. 2008;38(9):504–506. doi:10.1016/j.medmal.2008.06.006.
   PubMed Web of Science ®Google Scholar
• Klotz SA, Ianas V, Elliott SP. Cat-scratch disease. Am Fam Physician. 2011: 15;83(2): 152–155.
   PubMed Web of Science ®Google Scholar
• Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004;48(6):1921–1933. doi:10.1128/AAC.48.6.1921-1933.2004.
   PubMed Web of Science ®Google Scholar
• Biancardi AL, Curi AL. Cat-scratch disease. Ocul Immunol Inflamm. 2014;22(2):148–154. doi:10.3109/09273948.2013.833631.
   PubMed Web of Science ®Google Scholar
• Okun E, Butler WT. Ophthalmologic complications of cryptococcal meningitis. Arch Ophthalmol. 1964;71:52–57. doi:10.1001/archopht.1964.00970010068009.
   PubMedGoogle Scholar
• Kestelyn P, Taelman H, Bogaerts J, et al. Ophthalmic manifestations of infections with Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;116(6):721–727. doi:10.1016/S0002-9394(14)73472-5.
   PubMed Web of Science ®Google Scholar
• Skipper C, Abassi M, Boulware DR. Diagnosis and management of central nervous system cryptococcal infections in HIV-infected adults. J Fungi (Basel). 2019;5:3.
   Google Scholar
• Andreola C, Ribeiro MP, de Carli CR, Gouvea AL, Curi AL. Multifocal choroiditis in disseminated Cryptococcus neoformans infection. Am J Ophthalmol. 2006;142(2):346–348. doi:10.1016/j.ajo.2006.03.024.
   PubMed Web of Science ®Google Scholar
• Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore). 1993;72(4):207–224. doi:10.1097/00005792-199307000-00001.
   PubMed Web of Science ®Google Scholar
• Kempen J, Min Y, Freeman W, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmol. 2006;113:684–694. doi:10.1016/j.ophtha.2005.10.067.
   PubMed Web of Science ®Google Scholar
• Studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Foscarnet-ganciclovir cytomegalovirus retinitis trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Am J Ophthalmol. 1997;124:141–157. doi:10.1016/S0002-9394(14)70778-0.
   PubMed Web of Science ®Google Scholar
• Jabs D, Van Natta M, Holbrook J, Kempen J, Meinert C, Davis M. The studies of ocular complications of AIDS research group. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology. 2007;114(4):787–793. doi:10.1016/j.ophtha.2006.07.065.
   PubMed Web of Science ®Google Scholar
• Nguyen Q, Kempen J, Bolton S, Dunn J, Jabs D. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000;129(5):634–639. doi:10.1016/S0002-9394(00)00356-1.
   PubMed Web of Science ®Google Scholar
• Robinson M, Reed G, Csaky K, Polis M, Whitcup S. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol. 2000;130(1):49–56. doi:10.1016/S0002-9394(00)00530-4.
   PubMed Web of Science ®Google Scholar
• Karavellas M, Plummer D, Macdonald J, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. 1999;179(3):697–700. doi:10.1086/jid.1999.179.issue-3.
   PubMed Web of Science ®Google Scholar
• Jabs D. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome–bench to bedside: LXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011;151(2):198–216.e1. doi:10.1016/j.ajo.2010.10.018.
   PubMed Web of Science ®Google Scholar